Loading...
•
Sep 30, 2023
Collegium Q3 2023 Earnings Report
Collegium reported an 8% year-over-year increase in net revenue, reaching $136.7 million. GAAP net income was $20.6 million, and adjusted EBITDA reached a record $89.4 million, up 19% year-over-year.
Key Takeaways
Collegium Pharmaceutical, Inc. reported strong financial results for Q3 2023, with an 8% increase in net revenue to $136.7 million and a significant rise in GAAP net income to $20.6 million. The company also achieved a record adjusted EBITDA of $89.4 million, reflecting a 19% year-over-year growth. The company updated its full-year 2023 guidance.
Portfolio net revenue grew to $136.7 million, up 8% year-over-year.
Belbuca net revenue reached a record $45.4 million, up 17% year-over-year.
Xtampza ER net revenue was $39.8 million, up 2% year-over-year.
Nucynta Franchise net revenue increased to $47.5 million, up 7% year-over-year.
Revenue by Segment
Forward Guidance
The Company updates its full-year 2023 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA.
Positive Outlook
- Product Revenues, Net guidance updated to $565.0 to $570.0 million
- Adjusted Operating Expenses guidance updated to $125.0 to $130.0 million
- Adjusted EBITDA guidance updated to $360.0 to $365.0 million
- Extension of Nucynta's regulatory exclusivity through July 2026
- Successfully completed contract renegotiations with payors
Challenges Ahead
- Uncertainty of the expected financial performance of products
- Impact of the COVID-19 pandemic on business
- Dependence on commercialization and sales growth of products
- Reliance on relationships with licensors
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...